Last reviewed · How we verify
Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older
Approved treatments
- Oxbryta · Pfizer Inc.
Hemoglobin S polymerization inhibitor that binds HbS 1:1 and increases oxygen affinity.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older patent landscape — cliff calendar, originator estates, attackable patents
- Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older treatment landscape brief
- Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older treatment updates RSS
Frequently asked questions about Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older
What drugs treat Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older?
Tracked treatments include Oxbryta.
What is the treatment for Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older?
Standard treatment for Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older includes Oxbryta. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older patent cliff · Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older CI report
- Treatment: Oxbryta · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing